Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 10/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310202 | 1.00 | SIRT6 (0.61) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL3349400 | 0.85 | SIRT6 (0.58) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL15995584 | 0.84 | SIRT6 (0.69) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL3316399 | 0.82 | SIRT6 (0.73) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL12862128 | 0.82 | DPP4 (0.40) | SIRT6LMNAMAPTMAPK1 | |
| SCHEMBL3312558 | 0.81 | ADORA2A (0.40) | ALDH1A1 | |
| SCHEMBL3312565 | 0.81 | ADORA2A (0.40) | ALDH1A1 | |
| SCHEMBL13362115 | 0.81 | ADORA2A (0.40) | ALDH1A1 | |
| SCHEMBL3319515 | 0.81 | SIRT6 (0.60) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL3314034 | 0.77 | SIRT6 (0.55) | SIRT6ALDH1A1LMNAMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | SIRT6 1324/4885ALDH1A1 649/4885LMNA 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.